Zacks Investment Research cut shares of NuCana (NASDAQ:NCNA) from a buy rating to a hold rating in a report issued on Tuesday morning.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

NCNA has been the subject of a number of other reports. Cowen initiated coverage on NuCana in a research note on Monday, October 23rd. They set an outperform rating for the company. William Blair initiated coverage on NuCana in a research note on Monday, October 23rd. They set an outperform rating for the company. Citigroup initiated coverage on NuCana in a research note on Monday, October 23rd. They set a buy rating and a $23.00 price target for the company. Finally, Jefferies Group initiated coverage on NuCana in a research note on Monday, October 23rd. They set a buy rating and a $25.00 price target for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average price target of $21.00.

NuCana (NCNA) traded up $6.02 during trading on Tuesday, hitting $20.51. The company’s stock had a trading volume of 956,318 shares, compared to its average volume of 57,491. NuCana has a 1-year low of $9.32 and a 1-year high of $25.68.

Several large investors have recently made changes to their positions in the stock. Sphera Funds Management LTD. bought a new position in shares of NuCana during the 3rd quarter valued at approximately $919,000. Citadel Advisors LLC bought a new position in shares of NuCana during the 3rd quarter valued at approximately $1,218,000. Alyeska Investment Group L.P. bought a new position in shares of NuCana during the 3rd quarter valued at approximately $2,296,000. Perceptive Advisors LLC bought a new position in shares of NuCana during the 3rd quarter valued at approximately $3,674,000. Finally, Baillie Gifford & Co. bought a new position in shares of NuCana during the 3rd quarter valued at approximately $8,266,000. Institutional investors own 22.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Downgrades NuCana (NCNA) to Hold” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/20/zacks-investment-research-downgrades-nucana-ncna-to-hold.html.

About NuCana

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.